www ye7 live index ( MENAFN - UkrinForm) The resolution approved by the Cabinet of Ministers on the purchase of unmanned systems and electronic warfare equipment of domestic production will ensure stability, consistency and predictability for all participants in the process. Defense Minister Rustem Umerov wrote about this on facebook , Ukrinform reports. According to him, this includes simplification of procedures. Thus, commanders of military units can purchase drones and tactical-level electronic warfare without unnecessary bureaucratic approvals from the General Staff and other military authorities. The resolution also provides for expanded access to framework agreements: military units can join agreements concluded by the procurement agencies of the Ministry of Defense and the State Service for Special Communications and Information Protection. This will allow them to receive equipment faster and at competitive prices. Umerov emphasized that the Cabinet's decision ensures not only prompt delivery of the necessary technologies to the frontline, but also supports Ukrainian manufacturers by providing them with the opportunity to develop and improve their products. “From now on, the military will be able to plan their needs more efficiently, and manufacturers will be able to focus on technological development and production scaling,” he explained. As Ukrinform previously reported, on December 21, the government regulated the procedure for purchasing domestically produced unmanned systems and electronic warfare. MENAFN24122024000193011044ID1109028283 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Deep-pocketed investors have adopted a bearish approach towards NVIDIA NVDA , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVDA usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga's options scanner highlighted 279 extraordinary options activities for NVIDIA. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 43% leaning bullish and 46% bearish. Among these notable options, 26 are puts, totaling $1,945,197, and 253 are calls, amounting to $19,205,178. Projected Price Targets Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $104.0 to $191.0 for NVIDIA during the past quarter. Analyzing Volume & Open Interest Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in NVIDIA's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to NVIDIA's substantial trades, within a strike price spectrum from $104.0 to $191.0 over the preceding 30 days. NVIDIA Option Volume And Open Interest Over Last 30 Days Noteworthy Options Activity: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume NVDA CALL SWEEP BULLISH 12/27/24 $1.37 $1.36 $1.37 $142.00 $239.0K 33.8K 88.7K NVDA CALL SWEEP BULLISH 12/27/24 $1.38 $1.36 $1.37 $142.00 $164.2K 33.8K 85.6K NVDA CALL TRADE BEARISH 12/27/24 $1.04 $1.03 $1.03 $142.00 $144.5K 33.8K 68.8K NVDA CALL SWEEP BULLISH 12/27/24 $1.07 $1.06 $1.07 $142.00 $128.6K 33.8K 79.4K NVDA CALL SWEEP BEARISH 12/27/24 $1.41 $1.4 $1.4 $142.00 $128.3K 33.8K 94.4K About NVIDIA Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads. Following our analysis of the options activities associated with NVIDIA, we pivot to a closer look at the company's own performance. Current Position of NVIDIA Currently trading with a volume of 56,542,252, the NVDA's price is up by 1.1%, now at $141.21. RSI readings suggest the stock is currently may be approaching overbought. Anticipated earnings release is in 64 days. Turn $1000 into $1270 in just 20 days? 20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access . Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NVIDIA options trades with real-time alerts from Benzinga Pro . © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.FREYR Battery, Inc. FREY shares are trading higher on Tuesday. The company closed its acquisition of Trina Solar's 5 GW solar module manufacturing facility in Wilmer, Texas, announced last month . The transaction includes $100 million in cash, a $50 million loan repayment, a $150 million loan note, and 9.9% of FREYR's stock, with a potential additional 11.5% stake through an $80 million convertible note. FREYR also assumed $235 million in facility debt. The Wilmer, Texas, solar module plant is on track, with Line 1 completed and Line 2 commissioning underway. Full production is expected by the second half of 2025. FREYR plans to begin U.S. solar cell facility construction in second quarter of 2025, with regulatory filings starting in the first quarter of 2025. Approximately 30% of the production volume is already secured through firm offtake agreements with U.S. customers. FREYR also secured $50 million from Encompass Capital Advisors, with an additional $50 million contingent on the solar cell facility's construction. This acquisition enhances FREYR's solar and battery capabilities, positioning it for growth in renewable energy. Outlook : FREYR reiterated its 2025 EBITDA guidance of $75 million–$125 million, aiming for a $175 million–$225 million run rate by year-end . The company expects to achieve fully integrated operations to achieve an annual EBITDA of $650 million–$700 million . Daniel Barcelo, FREYR's Chairman of the Board and CEO said, "We are grateful for the continued support of our shareholders, and we look forward to advancing our key objectives to create meaningful shareholder value and to enhance our competitive position in 2025, highlighted by the planned start of construction of our solar cell manufacturing facility and other project development opportunities that are emerging for FREYR and Trina to mutually pursue." Last month, the company reported a third-quarter 2024 EPS loss of $(0.20), missing the consensus of $(0.18) . As of September 30, 2024, FREYR had cash, cash equivalents and restricted cash of $184.1 million. Price Action : FREY shares are up 13.30% at $3.90 at the last check on Monday. Read Next : Zoom Communications, Lockheed Martin And More: CNBC's ‘Final Trades' Photo Courtesy of Freyr Battery © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

FOXBOROUGH, Mass. (AP) — As spontaneous celebrations rippled throughout the Los Angeles Chargers' locker room after their resounding 40-7 win over the New England Patriots, coach Jim Harbaugh grabbed general manager Joe Hortiz and wrapped him up in a bear hug. “Love you!” Harbaugh said. “Love you!” Hortiz responded. “Great job! Let's keep it going,” Harbaugh replied, finally loosening his grasp. The Chargers (10-6) are back in the playoffs. But the message is clear: They have their eyes on achieving much more. Justin Herbert threw three touchdown passes and Los Angeles locked up its second playoff appearance in three seasons with Saturday's victory. “We had a good opportunity tonight and we went out and took it," Herbert said. “We had a good plan. All week we knew how big of a game this was for us. Guys were dialed in, focused and we executed today.” It also secured the fourth postseason appearance in Harbaugh’s five seasons as an NFL coach, adding to the three he made during his stint with the San Francisco 49ers. “You talk to them and there's more to do,” Harbaugh said. “There's no coach who could have it better than to be coaching these players. Nobody. Maybe the only person would be future us, could have it better than us.” Herbert finished 26 of 38 for 281 yards to become the third player in NFL history with at least 3,000 passing yards and 20 touchdown passes in each of his first five seasons. He joins Pro Football Hall of Famer Peyton Manning and Russell Wilson. Ladd McConkey had eight catches for 94 yards and pulled in TD throws of 6 and 40 yards. With a 10-yard reception in the second quarter, he passed 1,000 yards receiving for the season, making him the third Chargers rookie receiver to reach that milestone. JK Dobbins rushed 19 times for 76 yards and a TD. The Patriots (3-13) have lost six straight games, their second such losing streak of the season. They are now 2-14 the last two seasons at home. “We just didn’t play well enough in any phase of the game,” coach Jerod Mayo said. “No complementary football, and that’s what you get.” Asked if he thinks he is coaching for his job, Mayo said it comes with the territory. “I’m always under pressure and it’s been that way for a very long time, not just when I became the head coach of the Patriots," he said. New England quarterback Drake Maye finished 12 of 22 for 117 yards and a touchdown. He became the first rookie quarterback in franchise history with a TD pass in eight straight games. But he was sacked four times, and a second-quarter fumble marked his eighth straight game with at least one turnover. Los Angeles outgained New England 428-181 for the game. Maye briefly left the game to be evaluated for a head injury following a blow to his helmet in the first quarter. He was scrambling near the sideline on third down of the Patriots’ first possession when he was hit by Chargers cornerback Cam Hart, jarring the ball loose as Maye spun out of bounds. No flag was thrown on the play and Maye stayed down on the turf for several seconds before eventually getting up and jogging off the field. He initially sat on the bench before going to the medical tent for evaluation. He was replaced by backup Jacoby Brissett in the next series, which ended in a punt. But after further evaluation in the locker room and a Cameron Dicker 27-yard field goal put the Chargers in front 10-0, Maye returned to the game for the Patriots’ third series, at the 10:15 mark of the second quarter. Maye scrambled for 9 yards on his first play back, ending with him being hit by linebacker Junior Colson as he slid to the ground. Colson was flagged for unnecessary roughness. Five plays later, Maye mistimed a toss to Demario Douglas, causing a fumble that was recovered by Derwin James. The Chargers took over on the New England 24 and nine plays later, Herbert connected with McConkey for a 6-yard touchdown pass to put Los Angeles in front 17-0. Injuries Chargers: WR Joshua Palmer left the game in the third quarter with a heel injury. DB Elijah Molden limped off the field after a collision in the third quarter. He returned but was later driven off the field on a golf cart because of a shin injury. Patriots: In addition to Maye, CB Christian Gonzalez left the game in the second quarter to be evaluated for a head injury and was later ruled out with a concussion. Rookie record McConkey, a second-round draft selection, also set a Chargers rookie record for catches, surpassing Keenan Allen, who had 71 in 2013. Up next Chargers: Visit Las Vegas in their regular-season finale. Patriots: Host Buffalo next Sunday in their season finale. ___ AP NFL: https://apnews.com/hub/nfl Kyle Hightower, The Associated Press

NEW YORK (AP) — The man charged with killing UnitedHealthcare CEO Brian Thompson was not a client of the medical insurer and may have targeted it because of its size and influence, a senior police official said Thursday. NYPD Chief of Detectives Joseph Kenny told NBC New York in an interview Thursday that investigators have uncovered evidence that Luigi Mangione had prior knowledge UnitedHealthcare was holding its annual investor conference in New York City. Mangione also mentioned the company in a note found in his possession when he was detained by police in Pennsylvania. “We have no indication that he was ever a client of United Healthcare, but he does make mention that it is the fifth largest corporation in America, which would make it the largest healthcare organization in America. So that’s possibly why he targeted that company,” said Kenny. UnitedHealthcare is in the top 20 largest U.S. companies by market capitalization but is not the fifth largest. It is the largest U.S. health insurer. Mangione remains jailed without bail in Pennsylvania, where he was arrested Monday after being spotted at a McDonald's in the city of Altoona, about 230 miles (about 370 kilometers) west of New York City. His lawyer there, Thomas Dickey, has said Mangione intends to plead not guilty. Dickey also said he has yet to see evidence decisively linking his client to the crime. Mangione's arrest came five days after the caught-on-camera killing of Thompson outside a Manhattan hotel. Police say the shooter waited outside the hotel, where the health insurer was holding its investor conference, early on the morning of Dec. 4. He approached Thompson from behind and shot him before fleeing on a bicycle through Central Park. Mangione is fighting attempts to extradite him back to New York so that he can face a murder charge in Thompson's killing. A hearing has been scheduled for Dec. 30. The 26-year-old, who police say was found with a “ ghost gun ” matching shell casings found at the site of the shooting, is charged in Pennsylvania with possession of an unlicensed firearm, forgery and providing false identification to police. Mangione is an Ivy League graduate from a prominent Maryland real estate family. In posts on social media, Mangione wrote about experiencing severe chronic back pain before undergoing a spinal fusion surgery in 2023. Afterward, he posted that the operation had been a success and that his pain had improved and mobility returned. He urged others to consider the same type of surgery. On Wednesday, police said investigators are looking at his writings about his health problems and his criticism of corporate America and the U.S. health care system . Kenny said in the NBC interview that Mangione's family reported him missing to San Francisco authorities in November.

( MENAFN - GetNews) Ace Therapeutics released depression-related behavior tests to accelerate preclinical depression research. New York, USA - December 24, 2024 - Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and expedite the discovery of innovative therapeutic solutions. Depression is a pervasive global health challenge that affects millions of individuals, with current treatment options often proving ineffective or inaccessible. With the advancement of biotechnology and biological tools, such as diagnostic technology and animal model development, researchers can further investigate the mechanisms related to depression and thereby develop effective therapies targeting depression. Ace Therapeutics Psychiatry Team is committed to supporting scientists in making groundbreaking scientific discoveries and developing new applications to accelerate drug discovery and the scientific diagnosis and treatment of antipsychotic disorders. Its expert team can conduct depression behavior testing services to evaluate different components of depression in rodent models. For instance, the tail suspension and forced swim tests measure hopelessness, novelty-suppressed feeding measures apathy, and the sucrose preference test assesses anhedonia. In addition, tests to measure anxiety, including open field, elevated plus maze, and light/dark compartments, among others, often complement depression testing. By incorporating these specialized depression-related behavior tests into its preclinical depression research services, Ace Therapeutics aims to refine the evaluation of potential therapeutic candidates. In short, the newly implemented behavioral assays will evaluate a spectrum of depression-like symptoms, including anhedonia, social withdrawal, and despair, in preclinical animal models . This innovative approach enables researchers to gather critical data and draw correlations between specific behaviors and potential pharmacological responses. Such advancements may lead to more targeted and personalized treatments for those suffering from depression. In addition to depression behavior testing services, Ace Therapeutics also provides drug safety and efficacy studies, new antidepressant development, biomarker-based diagnostic development, and brain imaging diagnostic development, all to facilitate the research on depression, deepen understanding, and ultimately contribute to more effective treatments and interventions. About Ace Therapeutics With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative mental illness therapies. From basic research services to therapeutic development services, Ace Therapeutics offers tailored solutions to facilitate antipsychiatry studies, enabling the transformation of promising concepts into life-changing treatments. MENAFN24122024003238003268ID1109028227 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Lauren Boebert Abruptly Quits Controversial Cameo AccountTimberwolves didn’t turn to small ball to close last game, and those lineups don’t seem to be on the horizon